<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ymj</journal-id><journal-title-group><journal-title xml:lang="ru">Якутский медицинский журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Yakut Medical Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1813-1905</issn><issn pub-type="epub">2312-1017</issn><publisher><publisher-name>ЯНЦ КМП</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">ymj-1769</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Роль гепсидина в развитии анемии у пациентов с ювенильным ревматоидным артритом</article-title><trans-title-group xml:lang="en"><trans-title>The role of hepcidin in the development of anemia in patients with juvenile rheumatoid arthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Егоров</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Egorov</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Егоров Андрей Сергеевич – ст. лаб.</p></bio><bio xml:lang="en"><p>Egorov Andrey S. – senior assistant</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федорова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федорова Елена Владимировна – аспирант</p></bio><bio xml:lang="en"><p>Fedorova Elena V., assistant</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Часнык</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Chasnyk</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Часнык Вячеслав Григорьевич – д.м.н., проф.</p></bio><bio xml:lang="en"><p>MD, professor</p></bio><email xlink:type="simple">chasnyk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Винокурова</surname><given-names>Ф. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinokurova</surname><given-names>F. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Винокурова Фекла Васильевна – м.н.с.</p></bio><bio xml:lang="en"><p>junior researcher</p><p>Yakutsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский гос. педиатрич. мед. университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>SPbSPMA</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ЯНЦ КМП СО РАМН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>YSC CMP SB RAMS</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>09</month><year>2025</year></pub-date><volume>0</volume><issue>2</issue><fpage>42</fpage><lpage>45</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Егоров А.С., Федорова Е.В., Часнык В.Г., Винокурова Ф.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Егоров А.С., Федорова Е.В., Часнык В.Г., Винокурова Ф.В.</copyright-holder><copyright-holder xml:lang="en">Egorov A.S., Fedorova E.V., Chasnyk V.G., Vinokurova F.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ymj.elpub.ru/jour/article/view/1769">https://ymj.elpub.ru/jour/article/view/1769</self-uri><abstract><p>Считается, что гиперпродукция гепсидина в печени, обусловленная влиянием высокого уровня провоспалительных цитокинов, в первую очередь интерлейкина-6, играет ведущую роль в развитии анемии у пациентов с ювенильным ревматоидным артритом. По результатам обследования пациентов с ювенильным ревматоидным артритом, получающих терапию биологическими болезнь-модифицирующими лекарственными средствами (тоцилизумаб и голимумаб), прямой связи между уровнем гемоглобина и гепсидина не выявлено. Наиболее вероятно, что анемия при ревматоидном артрите обусловлена множеством факторов и связана как с нарушением метаболизма железа в организме, так и с негативным влиянием провоспалительных цитокинов на эритропоэз. Развитие тяжелой анемии, вероятно, сопряжено с сопутствующим дефицитом железа либо с развитием синдрома макрофагальной активации у детей с ювенильным ревматоидным артритом.</p></abstract><trans-abstract xml:lang="en"><p>Overproduction of hepcidin in the liver is considered to be due to the effect of high levels of proinflammatory cytokines. Interleukin-6 is known to play a key role in the development of anemia in patients with juvenile rheumatoid arthritis. During the study of patients with juvenile rheumatoid arthritis treated with biological disease-modifying drugs (tocilizumab and golimumab), direct relations between the level of hemoglobin and hepcidin were not found. Most probable, anemia in rheumatoid arthritis is multifactorial and involves violation of iron metabolism in the organism and the negative effects of proinflammatory cytokines on erythropoiesis. Severe anemia can be associated with iron deficiency or with the macrophage activation syndrome in children with juvenile rheumatoid arthritis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гепсидин</kwd><kwd>анемия</kwd><kwd>ювенильный ревматоидный артрит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepcidin</kwd><kwd>anemia</kwd><kwd>juvenile rheumatoid arthritis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров А.С. Распространенность анемии у пациентов с ювенильным ревматоидным артритом / А.С. Егоров, Е.В. Федорова // Ревматология в реальной клинической практике: VII всероссийская конференция. – Владимир, 2012. – С.21.</mixed-citation><mixed-citation xml:lang="en">Egorov A.S. The prevalence of anemia in patients with juvenile rheumatoid arthritis/ A.S. Egorov, E.V. Fedorova // Rheumatology in clinical practice: VII National Conference. – Vladimir, 2012. – Р.21.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis/ L.S. Ou, L.C. See, C.J. Wu [et al.] //Clin Rheumatol. 2002 Feb;21(1):52-6.</mixed-citation><mixed-citation xml:lang="en">Association between serum inflammatory cytokines and disease activity in juvenile idiopathic arthritis/ L.S. Ou, L.C. See, C.J. Wu [et al.] //Clin Rheumatol. 2002 Feb;21(1):52-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Association of anemia and physical disability among patients with rheumatoid arthritis/ C. Han, M.U. Rahman, M.K. Doyle [et al.] // J Rheumatol. 2007 Nov;34(11):2177-82.</mixed-citation><mixed-citation xml:lang="en">Association of anemia and physical disability among patients with rheumatoid arthritis/ C. Han, M.U. Rahman, M.K. Doyle [et al.] // J Rheumatol. 2007 Nov;34(11):2177-82.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bijlsma J.W. Methotrexate: still the anchor drug in RA treatment / J.W. Bijlsma, J.W. Jacobs // Joint Bone Spine. 2009 Oct;76(5):452-4.</mixed-citation><mixed-citation xml:lang="en">Bijlsma J.W. Methotrexate: still the anchor drug in RA treatment / J.W. Bijlsma, J.W. Jacobs // Joint Bone Spine. 2009 Oct;76(5):452-4.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Cartwright G.E. The anemia of infection. A review / G.E. Cartwright, M.M. Wintrobe // Adv Intern Med. 1952;5:165–226.</mixed-citation><mixed-citation xml:lang="en">Cartwright G.E. The anemia of infection. A review / G.E. Cartwright, M.M. Wintrobe // Adv Intern Med. 1952;5:165–226.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">CHARISMA Study Group. Doubleblind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate/ R.N. Maini, P.C. Taylor, J. Szechinski [et al.] // Arthritis Rheum. 2006 Sep;54(9):2817-29.</mixed-citation><mixed-citation xml:lang="en">CHARISMA Study Group. Doubleblind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate/ R.N. Maini, P.C. Taylor, J. Szechinski [et al.] // Arthritis Rheum. 2006 Sep;54(9):2817-29.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation / T. Ganz // Blood. 2003 Aug 1;102(3):783-8.</mixed-citation><mixed-citation xml:lang="en">Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation / T. Ganz // Blood. 2003 Aug 1;102(3):783-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hepcidin, a urinary antimicrobial peptide synthesized in the liver/ C.H. Park, E.V. Valore, A.J. Waring [et al.] // The Journal of Biological Chemistry. 2001. Vol. 276, No. 11: 7806–7810.</mixed-citation><mixed-citation xml:lang="en">Hepcidin, a urinary antimicrobial peptide synthesized in the liver/ C.H. Park, E.V. Valore, A.J. Waring [et al.] // The Journal of Biological Chemistry. 2001. Vol. 276, No. 11: 7806–7810.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood / G. Peslova, J. Petrak, K. Kuzelova [et al.] //Blood. 2009 Jun 11; 113(24):6225-36.</mixed-citation><mixed-citation xml:lang="en">Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood / G. Peslova, J. Petrak, K. Kuzelova [et al.] //Blood. 2009 Jun 11; 113(24):6225-36.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin/ E. Nemeth, S. Rivera, V. Gabayan [et al.] // J Clin Invest. 2004 May; 113(9): 1271-6.</mixed-citation><mixed-citation xml:lang="en">IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin/ E. Nemeth, S. Rivera, V. Gabayan [et al.] // J Clin Invest. 2004 May; 113(9): 1271-6.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study / M.C. Genovese, J.D. McKay, E.L. Nasonov [et al.] // Arthritis Rheum. 2008 Oct; 58(10):2968-80.</mixed-citation><mixed-citation xml:lang="en">Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseasemodifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study / M.C. Genovese, J.D. McKay, E.L. Nasonov [et al.] // Arthritis Rheum. 2008 Oct; 58(10):2968-80.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jayaranee S. Serum prohepcidin concentrations in rheumatoid arthritis/ S. Jayaranee, P. Sthaneshwar, S. Sokkalingam // Pathology. 2009 Feb; 41(2):178-82.</mixed-citation><mixed-citation xml:lang="en">Jayaranee S. Serum prohepcidin concentrations in rheumatoid arthritis/ S. Jayaranee, P. Sthaneshwar, S. Sokkalingam // Pathology. 2009 Feb; 41(2):178-82.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity / A. Krause, S. Neitz, H.J. Mägert [et al.] // FEBS Lett. 2000 Sep 1; 480(2-3):147-50.</mixed-citation><mixed-citation xml:lang="en">LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity / A. Krause, S. Neitz, H.J. Mägert [et al.] // FEBS Lett. 2000 Sep 1; 480(2-3):147-50.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Masson C.J. Rheumatoid anemia Rev / C.J. Masson // Joint Bone Spine 78 (2011) 131–137.</mixed-citation><mixed-citation xml:lang="en">Masson C.J. Rheumatoid anemia Rev / C.J. Masson // Joint Bone Spine 78 (2011) 131–137.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Means R.T. Jr. Hepcidin and anaemia/ R.T. Jr. Means // Blood Rev. 2004 Dec; 18(4):219-25.</mixed-citation><mixed-citation xml:lang="en">Means R.T. Jr. Hepcidin and anaemia/ R.T. Jr. Means // Blood Rev. 2004 Dec; 18(4):219-25.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Means R.T. Jr. Recent developments in the anemia of chronic disease/ R.T.Jr. Means / /Curr Hematol Rep. 2003; 2(2):116.</mixed-citation><mixed-citation xml:lang="en">Means R.T. Jr. Recent developments in the anemia of chronic disease/ R.T.Jr. Means / /Curr Hematol Rep. 2003; 2(2):116.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature/ A. Wilson, H.T. Yu, L.T. Goodnough [et al.] // Am J Med. 2004 Apr 5; 116 Suppl 7A:50S57S.</mixed-citation><mixed-citation xml:lang="en">Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature/ A. Wilson, H.T. Yu, L.T. Goodnough [et al.] // Am J Med. 2004 Apr 5; 116 Suppl 7A:50S57S.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry/ D.E. Furst, H. Chang, J.D. Greenberg [et al.] // Clin Exp Rheumatol. 2009 Jul-Aug; 27(4):560-6.</mixed-citation><mixed-citation xml:lang="en">Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry/ D.E. Furst, H. Chang, J.D. Greenberg [et al.] // Clin Exp Rheumatol. 2009 Jul-Aug; 27(4):560-6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus/ S.S. Koca., A. Isik, B. Ustundag [et al.] // Inflammation. 2008 Jun;31(3):146-53.</mixed-citation><mixed-citation xml:lang="en">Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus/ S.S. Koca., A. Isik, B. Ustundag [et al.] // Inflammation. 2008 Jun;31(3):146-53.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Synthetic hepcidin causes rapid dosedependent hypoferremia and is concentrated in ferroportin-containing organs / S. Rivera, E. Nemeth, V. Gabayan [et al.] // Blood. 2005 September 15; 106(6): 2196–2199.</mixed-citation><mixed-citation xml:lang="en">Synthetic hepcidin causes rapid dosedependent hypoferremia and is concentrated in ferroportin-containing organs / S. Rivera, E. Nemeth, V. Gabayan [et al.] // Blood. 2005 September 15; 106(6): 2196–2199.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">The iron exporter ferroportin / Slc40a1 is essential for iron homeostasis / A. Donovan, C.A. Lima, J.L. Pinkus [et al.] // Cell Metab. 2005 Mar; 1(3):191-200.</mixed-citation><mixed-citation xml:lang="en">The iron exporter ferroportin / Slc40a1 is essential for iron homeostasis / A. Donovan, C.A. Lima, J.L. Pinkus [et al.] // Cell Metab. 2005 Mar; 1(3):191-200.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials / M.K. Doyle, M.U. Rahman, C. Han et [et al.] // Semin Arthritis Rheum. 2009 Oct; 39(2):123-31.</mixed-citation><mixed-citation xml:lang="en">Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials / M.K. Doyle, M.U. Rahman, C. Han et [et al.] // Semin Arthritis Rheum. 2009 Oct; 39(2):123-31.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Young A. Extra-articular manifestations and complications of rheumatoid arthritis / A. Young, G. Koduri // Best Pract Res Clin Rheumatol. 2007 Oct; 21(5):907-27.</mixed-citation><mixed-citation xml:lang="en">Young A. Extra-articular manifestations and complications of rheumatoid arthritis / A. Young, G. Koduri // Best Pract Res Clin Rheumatol. 2007 Oct; 21(5):907-27.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
